Assay Detail
Functional
CHEMBL4821040
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiviral activity against SARS Cov-2 USA_WA1/2020 infected in Vero E6 cells assessed as inhibition of viral cytopathic effect measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
7
Total Activities
7
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Severe acute respiratory syndrome coronavirus 2 |
| Cell Type | Vero E6 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Target
SARS-CoV-2 (CHEMBL4303835) ↗| Type | ORGANISM |
| Organism | Severe acute respiratory syndrome coronavirus 2 |
Publication
Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 7 | 6.73 | 7.00 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL593726 | — | — | 1 | 7.00 |
| CHEMBL1448 | NICLOSAMIDE | 4.0 | 1 | 6.95 |
| CHEMBL2088014 | — | — | 1 | 6.89 |
| CHEMBL4466997 | — | — | 1 | 6.59 |
| CHEMBL2088010 | — | — | 1 | 6.50 |
| CHEMBL464249 | — | — | 1 | 6.42 |
| CHEMBL4871515 | — | — | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL593726 | — | IC50 | = | 101.0 | nM | 7.00 |
| CHEMBL1448 | NICLOSAMIDE | IC50 | = | 112.0 | nM | 6.95 |
| CHEMBL2088014 | — | IC50 | = | 128.0 | nM | 6.89 |
| CHEMBL4466997 | — | IC50 | = | 256.0 | nM | 6.59 |
| CHEMBL2088010 | — | IC50 | = | 320.0 | nM | 6.50 |
| CHEMBL464249 | — | IC50 | = | 380.0 | nM | 6.42 |
| CHEMBL4871515 | — | IC50 | = | 140.0 | % | - |